Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Xaluritamig · AMG 509

Bispecific antibody · Immune activation, directed at STEAP1 and CD3 (CD3D) · developed by AMGEN

Phase 3 Most advanced trial
AMGN Developer
1 Registered trials

What is Xaluritamig?

Xaluritamig is a humanized IgG1 bispecific antibody that binds STEAP1 on tumor cells and CD3 on T cells, cross-linking them to induce cytotoxic T-lymphocyte responses against STEAP1-expressing tumors. It is studied in metastatic castration-resistant prostate cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
AMG 509
Drug type
Bispecific antibody
Targets
STEAP1, CD3 (CD3D)
Mechanism
Immune activation, directed at STEAP1 and CD3 (CD3D)
Pathways
cytotoxic_T_lymphocyte_response
Therapy area
Oncology
Developer
AMGEN (AMGN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
ODG03B9M4U

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07213674 Phase 3 Metastatic Castration-resistant Prostate Cancer Recruiting AMGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Metastatic Castration-resistant Prostate Cancer

Other drugs acting on STEAP1 / CD3D

Tarlatamab FDA approved CTIM-76 Phase 1 ZW171 Phase 1

More from AMGEN

Apremilast FDA approved Blinatumomab FDA approved Carfilzomib FDA approved Denosumab FDA approved Erenumab FDA approved Evolocumab FDA approved Pegloticase FDA approved Prednisone FDA approved Romiplostim FDA approved Romosozumab FDA approved Sotorasib FDA approved Tarlatamab FDA approved

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the AMGN page.

Follow AMGN, the company behind Xaluritamig

See AMGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AMGN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.